Viemed Healthcare VMD
- Market cap
- $373.3M
- PE
- 27.2×
- 7y median 26.1×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.2×
- EV/EBIT
- 16.3×
- Revenue, 12 months
- $301.6M
- +25% on a year ago
- Net margin
- 4.8%
- Free cash flow yield
- 7.8%
Viemed Healthcare trades at 27.2× trailing earnings, near its ten-year median. Revenue was $301.6M over the last twelve months, up 25% on a year earlier with a 5% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $49.4M+38% | $50.7M+35% | $50.6M+28% | $55M+27% | $58M+17% | $60.7M+20% | $59.1M+17% | $63.1M+15% | $71.9M+24% | $76.2M+26% | $75.4M+28% | $78.1M+24% | |
| Cost of revenue | $18.8M+34% | $18.6M+28% | $20.8M+34% | $22.1M+28% | $23.6M+25% | $24.6M+32% | $25.9M+24% | $26.3M+19% | $30.6M+29% | $32.1M+31% | $32.6M+26% | $33M+26% |
| Gross profit | $30.6M+41% | $32.1M+40% | $29.8M+24% | $32.9M+26% | $34.4M+13% | $36.1M+13% | $33.3M+12% | $36.7M+12% | $41.3M+20% | $44.1M+22% | $42.8M+29% | $45M+23% |
| R&D | $593K−12% | $651K−10% | $750K−4% | $758K+0% | $757K+28% | $803K+23% | $797K+6% | $847K+12% | $775K+2% | $598K−26% | $579K−27% | $504K−41% |
| SG&A | $23.7M+34% | $23.9M+39% | $24.8M+26% | $26.5M+29% | $26.7M+13% | $28.2M+18% | $28.4M+15% | $28.8M+9% | $31.9M+20% | $32.2M+14% | $34.8M+22% | $37.1M+29% |
| $4.2M+186% | $5.3M+50% | $2.2M+14% | $3.6M+25% | $5.6M+34% | $6.5M+22% | $3.8M+74% | $5.1M+41% | $5.6M+0% | $8.4M+30% | $4.3M+12% | $4.5M−12% | |
| Interest expense | $237K+464% | $256K+700% | $150K | $254K | $225K−5% | $147K−43% | $179K+19% | $132K−48% | $507K+125% | $364K+148% | $305K+70% | $248K+88% |
| Pre-tax income | $4.2M+181% | $5.1M+42% | $2.1M+5% | $2.2M−27% | $5.5M+30% | $6.3M+24% | $3.7M+73% | $5M+121% | $5.1M−7% | $8M+27% | $4M+9% | $4.1M−18% |
| $1.3M+190% | $1.6M+40% | $518K+3% | $768K+6% | $1.6M+21% | $1.9M+18% | $952K+84% | $1.7M+123% | $1.5M−4% | $2.2M+17% | $1.3M+34% | $1.2M−33% | |
| Net income | $2.9M+177% | $3.5M+43% | $1.6M+6% | $1.5M−37% | $3.9M+33% | $4.3M+24% | $2.6M+64% | $3.2M+115% | $3.5M−9% | $5.6M+31% | $2.6M−2% | $2.8M−12% |
| $0.07+133% | $0.09+50% | $0.04+0% | $0.04−33% | $0.10+43% | $0.10+11% | $0.06+50% | $0.08+100% | $0.09−10% | $0.14+40% | $0.06+0% | $0.07−13% | |
| 40.4M+2% | 40.3M+2% | 40.6M+1% | 40.6M−0% | 40.8M+1% | 41.1M+2% | 41.6M+3% | 41.1M+1% | 40.5M−1% | 40M−3% | 40.5M−3% | 41.1M+0% |
Cost of revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
R&D: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Income tax: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
EPS, diluted: 7 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. 7 periods, Q4 FY18 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Viemed Healthcare's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| VMDViemed Healthcare | $373.3M | 27.2× | 26.1× | 1.2× | +25% | 4.8% | |
| SBCSBC Medical | $543M | 11.2× | 8.2× | 3.1× | −7% | 28.0% | |
| OMDAOmada Health | $1.2B | 316× | 341× | 3.7× | +48% | 1.4% | |
| USPHU S Physical Therapy | $1.3B | 101× | 42.1× | 1.6× | +11% | 4.0% | |
| PNTGPennant | $1.5B | 46.5× | 47.0× | 1.3× | +38% | 2.9% | |
| ARDTArdent Health | $1.7B | 22.3× | 8.5× | 0.3× | +3% | 1.2% | |
| HCSGHealthcare Services | $1.7B | 14.7× | 26.1× | 0.9× | +4% | 6.6% | |
| PGNYProgyny | $2.2B | 31.5× | 55.1× | 1.7× | +6% | 6.0% | |
| ADUSAddus HomeCare | $2.3B | 21.4× | 32.4× | 1.5× | +16% | 7.1% | |
| MDPediatrix Medical | $2.4B | 14.0× | 13.4× | 1.2× | +1% | 9.0% | |
| PRVAPrivia Health | $2.9B | 107× | 158× | 1.2× | +24% | 1.2% | |
| Peer median | $1.7B | 26.9× | 37.2× | 1.4× | +8% | 5.0% |
More on Viemed Healthcare
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .